USX:ENZ - Enzo Biochem, Inc (USD 2.5) Enzo Biochem, Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
Add Alert 

Yahoo Finance

USD 2.5    -0.010 (-0.40%)
Show Technical Chart | 1M    3M    6M    1Y    3Y    5Y         

14 Aug 2020


14 Aug 2020

Day Change: -0.010 (-0.40%)

52 Wk Range: 1.56 - 4.85

Day's Range: 2.46 - 2.515

Last Volume: 219,787

Current Yield: 0%

Projected Yield: 0%

Open: USD 2.5

14 Aug 2020

Metric ENZ S.Median
Beta 0.47 0.41
VaR 49.06 53.4
E.Shortfall 78.9 88.57
Liquidity 317.68K 1,565.11


14 Aug 2020

PE: -3.881

Market Cap: 119.7M

Price Over Book: 1.921

Price Over Sales: 1.55

Return On Assets: -26.3%

Return On Equity: -49.1%

Current Ratio: 2.269


CEO: Dr. Elazar Rabbani

Headquarters: US

Employees: 460

Sector: Health Technology

Industry: Medical Specialties

Useful Links


Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in Life Sciences Products, Clinical Laboratory Services, and Therapeutics segments. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 34 patient service centers in New York and New Jersey; and a free standing ?STAT' or rapid response laboratory in New York City and Connecticut, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.